Roth Capital Maintains Buy On China Cord Blood Corporation, Increases PT To $6
In a research note issued this morning, Roth Capital analyst Scott Henry maintained a Buy rating on China Cord Blood Corporation (CO) and raised his price target to $6.00 (from $5.00) following 4Q14 results that were largely in-line with expectations.
“We viewed the quarter for CO within the range of expectations. We further are hopeful that the Year of the Dragon hangover should now be over. The higher price target is motivated by increased cash and a strong growth outlook for FY2016”, said Henry.
According to TipRanks, which measures analysts and bloggers success rate based on how their calls perform, analyst Scott Henry currently has a one-year average return of 33.7% and a 55% success rate. He is ranked #388 out of 3118 analysts.